Zenas BioPharma(ZBIO)
WALTHAM, MAPharmaceutical
Focus: Zenas BioPharma is a publicly traded immunology-focused biopharmaceutical company founded in 2020, developing immune-based therapies across neurology, immunology, and endocrinology. The company is in a high-growth clinical stage with multiple Phase 3 programs advancing toward regulatory milestones.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
14-3 this month
Stable — net -3 jobs in 30d
3 added, 6 removed. Backfill posture.
Should You Work at Zenas BioPharma?
AI assessmentZenas offers meaningful upside for risk-tolerant professionals betting on imminent Phase 3 readouts and commercialization, but sustainability depends entirely on regulatory success in the next 12–24 months.
Why Work Here
- Strong cash position of $320M (FY 2025) provides runway and reduced near-term funding risk, unusual for a 2020-founded biotech.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$5M
Pipeline & Clinical Trials
ZB001 for injection
Healthy VolunteersClinical Trials (1)
NCT05542303A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects
Phase 1Help build intelligence for Zenas BioPharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.